Breaking Research News from sources other than Breastcancer.org
Comments
-
Long-Term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy in Metastatic Triple-Negative Breast Cancer
- Study published in: JAMA Oncology
- https://www.practiceupdate.com/C/73363/56?elsca1=e...
Excerpt from editorial comment by Lee S. Schwartzberg MD, FACPThe long-term results of this phase I study of atezolizumab ... furthers the evidence base substantially. Most importantly, there appears to be a substantial fraction of TNBC patients who enjoy long-term survival after monotherapy with atezolizumab.0 -
Prognostic Value of the Progesterone Receptor by Subtype in Patients With ER+, HER2− Breast Cancer
Study appeared in:The Oncologist
https://www.practiceupdate.com/C/72828/56?elsca1=e...
- This retrospective study evaluated the prognostic value of progesterone receptor (PR) status by histologic subtype of ER+/HER2− breast cancer. Absence of the PR receptor predicted worse outcomes.
- Absence of the PR receptor appears to be more important in tumors with a high rate of proliferative activity versus those with a low rate.
0 -
9 Weeks vs 1 Year Adjuvant Trastuzumab Plus Chemotherapy in HER2+ Breast Cancer
- Published in: Annals of Oncology
- https://www.practiceupdate.com/C/73412/56?elsca1=e...
0 -
Trends in Breast Cancer Mortality by Stage at Diagnosis Among Young Women in the United States
- Published in: Cancer
- https://www.practiceupdate.com/C/73089/56?elsca1=e...
0 -
Novel 18-Gene Signature for Predicting Relapse in ER+, HER2− Breast Cancer
- Published in: Breast Cancer Research
- https://www.practiceupdate.com/C/73095/56?elsca1=e...
0 -
I wish they would have posted some symptoms for each individual "spread" site. Since I have ILC, what would the symptoms of a peritoneal spread feel or look like?
0 -
claireinaz: I don't know but maybe try this forum:
https://community.breastcancer.org/forum/8/topics/...
... and you can search for others.
Good luck!
0 -
OMG, Lumpie, that thread is terrifying. I only saw that someone reported their tumor markers were elevated, but my MO doesn't rely on tumor markers. Quite frankly I stopped reading after just a few responses--they all talk about ascites, which seem to swell bellies out and cause nausea and bloating, and I remember my late husband in his late stages of cancer having to have his ascites from his pleural space drawn off every few days so he could breathe.
I think I'll tell myself no need to borrow trouble, and hope for the best.
Thanks, though~~
0 -
Claireinaz, Sorry it was disturbing! You are right - no need to borrow trouble (great saying). Worry another day.
0 -
Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment
- Published in Journal of Clinical Oncology
- https://www.practiceupdate.com/C/73752/56?elsca1=e...
ARTICLE CITATION
DOI: 10.1200/JCO.2018.78.6624 Journal of Clinical Oncology
0 -
Most Breast Cancer Diagnoses Given Over the Phone
This represents a reversal, with in-person diagnoses more common before 2006
- HealthDay
- https://www.practiceupdate.com/C/73875/56?elsca1=e...
- Almost 60 percent of participants diagnosed from 2015 to 2017 learned about their diagnosis over the telephone. "When we analyzed the data, I was completely surprised to find such a clear trend," ... "Historically, physicians have decided to use their best judgment when delivering a diagnosis, whether it's in person or over the phone. Nowadays, some patients clearly want to hear this information over the phone."
0 -
Study: 45.2% of US resident physicians experience burnout Researchers surveyed US resident physicians and found that 14.1% reported career choice regret, while 45.2% reported symptoms of burnout. The findings, published in the Journal of the American Medical Association, showed significant associations between career choice regret and reported symptoms of burnout as well as clinical specialty.Physician's Briefing/HealthDay News
http://www.physiciansbriefing.com/Article.asp?AID=...
https://jamanetwork.com/journals/jama/article-abst...
JAMA. 2018;320(11):1114-1130. doi:10.1001/jama.2018.12615
{Since this issue impacts the environment of care, I thought it legitimate to share this news. Troubling, but not surprising.}
0 -
Lumpie - thanks again for all your posts. What I particularly like is the quick summary so each of us can decide it is relates to us before wading through all the detailed reports.
0 -
I agree. It is so helpful to learn a bit and determine if it's a study that we want to read or not. And I appreciate the wide range of topics, too.
0 -
Paying for Cancer Care at All Costs
https://www.curetoday.com/articles/paying-for-canc...
Financial toxicity, and the short- and long-term impact that it has on patients' well-being, continues to gain more and more attention. This article discusses new survey results that provide further insights into how much patients are willing to sacrifice, including 49% of respondents saying they're willing to declare bankruptcy. It is further evidence that while some progress is being made, a lot of work still continues to protect more patients and their families from the high costs of cancer care.
0 -
Treatment of Brain Metastases With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors
- Published in: Radiotherapy & Oncology
- https://www.practiceupdate.com/C/73718/56?elsca1=e...
0 -
APNewsBreak: EPA says a little radiation may be healthy
https://apnews.com/6a573b6b020e453c90ecd5e84aa23f5...0 -
Study evaluates personalized vaccine in treating various cancers
Published in HealthDay 10/1/2018
https://consumer.healthday.com/cancer-information-...
Researchers found that six of 11 individuals with HER2-positive cancers who received personalized HER2-targeting vaccine had clinical benefit, including one patient with ovarian cancer achieving complete response lasting 89 weeks and another with gastroesophageal cancer reaching partial response lasting for months. The findings were presented at a joint meeting of the American Association for Cancer Research, the Association for Cancer Immunotherapy, the Cancer Research Institute and the European Academy of Tumor Immunology.
"...it's a good sign to see an apparent benefit in a phase 1 trial, but cautioned that the research is "incredibly early. It's too early to start jumping for joy. They show some clear evidence of a benefit, and it's a good investment to pursue this lead."
The researchers plan on combining the current vaccine with a drug that can help overcome a cancer's ability to suppress the immune system in the next phase of research. The drugs are called checkpoint inhibitors.
The findings were presented Sunday at a meeting sponsored by the Cancer Research Institute, the Association of Cancer Immunotherapy, the European Academy of Tumor Immunology and the American Association for Cancer Research, in New York City. Research presented at meetings should be considered preliminary until published in a peer-reviewed journal.
0 -
On Oct 1st Dr. James P Allison, of M.D. Anderson, along with Dr Tasuko Honjo of Japan, won a shared Nobel Prize in Medicine for their individual ground-breaking immunotherapy research on cancer.
0 -
Carefully Selected News and Features About Metastatic Breast Cancer Research
Watch Meetings From Across the U.S.
A number of local and national conferences focused specifically on metastatic breast cancer take place throughout the country each year. On this page you will find links to conferences that took place over the past year in Seattle, Boston, Chicago and Los Angeles.
You can also find a link to the CSPAN recording of Former Vice President Joe Biden's keynote remarks at the inaugural annual summit of the Biden Cancer Initiative, held in Washington, DC. This is not specific to metastatic breast cancer, but it provides insights into new directions in cancer research.
https://metastatictrialtalk.org/2018/10/03/confere...
0 -
FDA Public Workshop: Partners in Progress 2018 - Cancer Patient Advocates and FDA
The FDA Oncology Center of Excellence will hold its second annual educational workshop for new cancer patient advocates, Partners in Progress: Cancer Patient Advocates and FDA. The objectives are to provide basic training on the role of the FDA and cancer patient advocates in oncology product development. This broad introduction to FDA regulatory aspects of oncology product development is most relevant to attendees with limited knowledge and experience in cancer product development and patient advocacy.
Date: November 27, 2018
Time: 9:00 am to 4:00 pm
{Both remote/webcast and in-person participation are options. Registration required.}
https://www.fda.gov/AboutFDA/CentersOffices/Office...
0 -
Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer
- Journal of the National Cancer Institute This pooled analysis used gene expression profiling data along with pooled individual-level data (7 trials including 1778 patients) to determine the impact of omitting radiotherapy on recurrence and mortality rates associated with stage I, ER+/PR+, HER2− breast cancer.Although omission of radiotherapy was associated with a small increase in locoregional recurrence, the researchers uncovered no evidence that omitting it made any difference the rate of distant recurrence or in survival.
0 -
Second Opinion at NCI Center Valuable for Breast Cancer Patients
Almost 43 percent of those presenting to NCI center for second opinion have change in diagnosis
- HealthDay Oct. 2, 2018
- https://www.practiceupdate.com/C/74304/56?elsca1=e...
- Further reporting on same topic here:
- https://www.news-medical.net/news/20180926/Study-S...
- Originally Published in the Annals of Surgical Oncology
0 -
Pathological Response and Survival in TNBC After Neoadjuvant Carboplatin + Docetaxel
Published in: Clinical Cancer Research
- This study looked at recurrence-free and overall survival according to the degree of pathologic response in patients with stage I–III triple-negative breast cancer treated with neoadjuvant carboplatin plus docetaxel. The rate of pathological complete response (pCR) was 55%. The rate of residual cancer burden class I was 13%. At 3 years, overall survival for patients with pCR was 94% vs 79% for those without pCR.
- These results indicate that neoadjuvant carboplatin plus docetaxel shows promise in extending survival in patients with triple-negative breast cancer.
0 -
Paclitaxel With Inhibitor of Apoptosis Antagonist LCL161 for Localized Triple-Negative Breast Cancer
- Journal of Clinical Oncology Women with localized triple-negative breast cancer (T2/N0–2/M0) were prospectively stratified by a tumor necrosis factor-α (TNFα)–based gene expression signature (GS) and randomly assigned to receive oral LCL161 (inhibitor of apoptosis antagonist) and intravenous paclitaxel or paclitaxel alone for 12 weeks, followed by surgery. Those in the GS-positive group experienced improved pathologic complete response with combination therapy relative to paclitaxel alone (38.2% vs 17.2%). For patients in the GS-negative group, pathologic complete response was inferior with combination therapy relative to paclitaxel alone (5.6% vs 16.4%). Patients receiving combination therapy experienced higher rates of adverse events such as neutropenia (24.5%) and diarrhea (5.7%) and were more likely to discontinue treatment due to adverse events than were patients receiving paclitaxel alone (18.1% vs 4.9%).The study authors conclude that the biomarker-driven targeted therapy approach shows promise in terms of efficacy; however, elevate rates of adverse events must be taken into consideration.This neoadjuvant trial provides evidence supporting a biomarker-driven targeted therapy approach for selected patients with GS-positive TNBC and demonstrates the utility of a neoadjuvant trial for biomarker validation and drug development, but also highlights toxicity risk. Future neoadjuvant clinical trials should carefully weigh these considerations for targeted therapy development in biomarker-defined TNBC.
DOI: 10.1200/JCO.2017.74.8392 Journal of Clinical Oncology
PMID: 30235087
0 -
Metastatic Breast Cancer: Later Lines of Therapy
- Expert Opinion / Interview · April 11, 2018
- Video Interviews with practitioners
- https://www.practiceupdate.com/content/metastatic-...
- {This is a few months old but interesting.}
0 - Expert Opinion / Interview · April 11, 2018
-
Prognostic Value of CD3, CD8, and FOXP3 mRNA Expression in Early-Stage Breast Cancer Patients Treated With Anthracycline-Based Adjuvant Chemotherapy
- Published in: Cancer Medicine @ October 08, 2018
- https://www.practiceupdate.com/C/73757/56?elsca1=e...
- First published: 21 September 2018 https://doi.org/10.1002/cam4.1730 This study evaluated 826 tumor tissue samples for mRNA expression of CD3, CD8, and FOXP3 for potential prognostic significance in terms of disease‐free and overall survival among patients with early‐stage breast cancer treated with anthracycline‐based chemotherapy.High CD3 and CD8 mRNA expression was found to be prognostic of decreased risk of relapse and, in the future, could potentially be of importance in deciding the most appropriate therapeutic strategy in light of recent immune‐related treatment developments.
0 -
Screening does not reduce breast cancer mortality
https://www.news-medical.net/news/20180912/Screeni...
published in the scientific journal International Journal of Cancer
"....Here he points towards one of the paradoxes of screening - the popular but erroneous belief that if breast cancer patients who have been screened 'live longer' than other breast cancer patients, then screening works. The problem is that with screening, medical doctors detect cancerous tumors earlier than they would otherwise have done, and thus move the point of diagnosis forward in time. But even if someone who has been screened lives longer as a patient, it is not certain that their life as a whole will be longer. It is important to account for this fact, and the new study shows that screening does not lead to women living longer overall - and this is the study's most important finding."
Original source: http://www.au.dk/
0 -
Aggressive breast cancer cells hijack protective protein to aid growth
reported in the journal Oncogene
DOI https://doi.org/10.1038/s41388-018-0472-0
A study conducted at Augusta University has revealed that a protein known to protect healthy cells also protects cancer cells in aggressive breast cancer.
https://www.news-medical.net/news/20181002/Protein...
Further reporting at: https://www.eurekalert.org/pub_releases/2018-10/mc...
0 -
Stevens researchers develop new class of molecules for breast cancer treatment
https://www.news-medical.net/news/20181004/Stevens...
Researchers at Stevens Institute of Technology and colleagues have designed and developed a new class of molecules that use a never-before-known mechanism that may halt or destroy breast cancer tumors, particularly for patients with drug-resistant or dangerously metastatic stages of the disease.
The molecule, developed by Abhishek Sharma, a chemistry professor at Stevens, could potentially add to the arsenal of drugs actively being developed to degrade or inhibit estrogen receptors, proteins inside cells that have been proven to be the single most important target in breast cancer therapy over the last 30 years.
https://www.stevens.edu/news/novel-molecule-could-...
published in the journal ACS Medicinal Chemistry Letters (Publication Date (Web): July 5, 2018)
DOI: 10.1021/acsmedchemlett.8b00106
0
